Dopamine D2 receptor occupancy with risperidone or olanzapine during maintenance treatment of schizophrenia

A cross-sectional study

Yuya Mizuno, Robert Bies, Gary Remington, David C. Mamo, Takefumi Suzuki, Bruce G. Pollock, Takashi Tsuboi, Koichiro Watanabe, Masaru Mimura, Hiroyuki Uchida

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

In treating schizophrenia, it has been established that 65-80% occupancy of dopamine D2 receptors optimizes therapeutic efficacy while minimizing risks of extrapyramidal symptoms. However, it is unclear as to whether it is necessary to keep D2 receptor occupancy within this therapeutic window to maintain response. In this study, daily peak and trough D2 receptor occupancy levels were estimated in clinically stable patients with schizophrenia (DSM-IV) who were receiving risperidone or olanzapine. Using two collected plasma samples, plasma antipsychotic concentrations at peak and trough were estimated with population pharmacokinetic techniques. Corresponding dopamine D2 receptor occupancy levels were then estimated, using a recently developed model. 35 subjects with stable schizophrenia completed the study (mean ± SD age, 48.8 ± 13.8. years; male [N = 14]; Asians [N = 23], Caucasians [N = 12]; risperidone [N = 20] at 3.2 ± 2.3. mg/day, and olanzapine [N = 15] at 9.2 ± 4.9. mg/day) between September and December 2010. 48.6% (N = 17) did not achieve a continuous blockade of ≥ 65%. Moreover, 11.4% (N = 4) did not achieve the 65% threshold at estimated peak concentrations. In conclusion, approximately half the subjects with stable schizophrenia did not achieve estimated continuous blockade of D2 receptor occupancy of ≥ 65%. The results suggest that sustained D2 receptor occupancy levels of ≥ 65% may not always be necessary for the maintenance treatment of schizophrenia.

Original languageEnglish
Pages (from-to)182-187
Number of pages6
JournalProgress in Neuro-Psychopharmacology and Biological Psychiatry
Volume37
Issue number1
DOIs
StatePublished - Apr 27 2012

Fingerprint

olanzapine
Risperidone
Dopamine D2 Receptors
Schizophrenia
Cross-Sectional Studies
Therapeutics
Diagnostic and Statistical Manual of Mental Disorders
Antipsychotic Agents
Pharmacokinetics

Keywords

  • Antipsychotic
  • Dopamine
  • Maintenance
  • Olanzapine
  • Risperidone
  • Schizophrenia

ASJC Scopus subject areas

  • Biological Psychiatry
  • Pharmacology

Cite this

Dopamine D2 receptor occupancy with risperidone or olanzapine during maintenance treatment of schizophrenia : A cross-sectional study. / Mizuno, Yuya; Bies, Robert; Remington, Gary; Mamo, David C.; Suzuki, Takefumi; Pollock, Bruce G.; Tsuboi, Takashi; Watanabe, Koichiro; Mimura, Masaru; Uchida, Hiroyuki.

In: Progress in Neuro-Psychopharmacology and Biological Psychiatry, Vol. 37, No. 1, 27.04.2012, p. 182-187.

Research output: Contribution to journalArticle

Mizuno, Yuya ; Bies, Robert ; Remington, Gary ; Mamo, David C. ; Suzuki, Takefumi ; Pollock, Bruce G. ; Tsuboi, Takashi ; Watanabe, Koichiro ; Mimura, Masaru ; Uchida, Hiroyuki. / Dopamine D2 receptor occupancy with risperidone or olanzapine during maintenance treatment of schizophrenia : A cross-sectional study. In: Progress in Neuro-Psychopharmacology and Biological Psychiatry. 2012 ; Vol. 37, No. 1. pp. 182-187.
@article{0b4fe3511fc848048fe9d6cc9fe8a5be,
title = "Dopamine D2 receptor occupancy with risperidone or olanzapine during maintenance treatment of schizophrenia: A cross-sectional study",
abstract = "In treating schizophrenia, it has been established that 65-80{\%} occupancy of dopamine D2 receptors optimizes therapeutic efficacy while minimizing risks of extrapyramidal symptoms. However, it is unclear as to whether it is necessary to keep D2 receptor occupancy within this therapeutic window to maintain response. In this study, daily peak and trough D2 receptor occupancy levels were estimated in clinically stable patients with schizophrenia (DSM-IV) who were receiving risperidone or olanzapine. Using two collected plasma samples, plasma antipsychotic concentrations at peak and trough were estimated with population pharmacokinetic techniques. Corresponding dopamine D2 receptor occupancy levels were then estimated, using a recently developed model. 35 subjects with stable schizophrenia completed the study (mean ± SD age, 48.8 ± 13.8. years; male [N = 14]; Asians [N = 23], Caucasians [N = 12]; risperidone [N = 20] at 3.2 ± 2.3. mg/day, and olanzapine [N = 15] at 9.2 ± 4.9. mg/day) between September and December 2010. 48.6{\%} (N = 17) did not achieve a continuous blockade of ≥ 65{\%}. Moreover, 11.4{\%} (N = 4) did not achieve the 65{\%} threshold at estimated peak concentrations. In conclusion, approximately half the subjects with stable schizophrenia did not achieve estimated continuous blockade of D2 receptor occupancy of ≥ 65{\%}. The results suggest that sustained D2 receptor occupancy levels of ≥ 65{\%} may not always be necessary for the maintenance treatment of schizophrenia.",
keywords = "Antipsychotic, Dopamine, Maintenance, Olanzapine, Risperidone, Schizophrenia",
author = "Yuya Mizuno and Robert Bies and Gary Remington and Mamo, {David C.} and Takefumi Suzuki and Pollock, {Bruce G.} and Takashi Tsuboi and Koichiro Watanabe and Masaru Mimura and Hiroyuki Uchida",
year = "2012",
month = "4",
day = "27",
doi = "10.1016/j.pnpbp.2011.12.013",
language = "English",
volume = "37",
pages = "182--187",
journal = "Progress in Neuro-Psychopharmacology and Biological Psychiatry",
issn = "0278-5846",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Dopamine D2 receptor occupancy with risperidone or olanzapine during maintenance treatment of schizophrenia

T2 - A cross-sectional study

AU - Mizuno, Yuya

AU - Bies, Robert

AU - Remington, Gary

AU - Mamo, David C.

AU - Suzuki, Takefumi

AU - Pollock, Bruce G.

AU - Tsuboi, Takashi

AU - Watanabe, Koichiro

AU - Mimura, Masaru

AU - Uchida, Hiroyuki

PY - 2012/4/27

Y1 - 2012/4/27

N2 - In treating schizophrenia, it has been established that 65-80% occupancy of dopamine D2 receptors optimizes therapeutic efficacy while minimizing risks of extrapyramidal symptoms. However, it is unclear as to whether it is necessary to keep D2 receptor occupancy within this therapeutic window to maintain response. In this study, daily peak and trough D2 receptor occupancy levels were estimated in clinically stable patients with schizophrenia (DSM-IV) who were receiving risperidone or olanzapine. Using two collected plasma samples, plasma antipsychotic concentrations at peak and trough were estimated with population pharmacokinetic techniques. Corresponding dopamine D2 receptor occupancy levels were then estimated, using a recently developed model. 35 subjects with stable schizophrenia completed the study (mean ± SD age, 48.8 ± 13.8. years; male [N = 14]; Asians [N = 23], Caucasians [N = 12]; risperidone [N = 20] at 3.2 ± 2.3. mg/day, and olanzapine [N = 15] at 9.2 ± 4.9. mg/day) between September and December 2010. 48.6% (N = 17) did not achieve a continuous blockade of ≥ 65%. Moreover, 11.4% (N = 4) did not achieve the 65% threshold at estimated peak concentrations. In conclusion, approximately half the subjects with stable schizophrenia did not achieve estimated continuous blockade of D2 receptor occupancy of ≥ 65%. The results suggest that sustained D2 receptor occupancy levels of ≥ 65% may not always be necessary for the maintenance treatment of schizophrenia.

AB - In treating schizophrenia, it has been established that 65-80% occupancy of dopamine D2 receptors optimizes therapeutic efficacy while minimizing risks of extrapyramidal symptoms. However, it is unclear as to whether it is necessary to keep D2 receptor occupancy within this therapeutic window to maintain response. In this study, daily peak and trough D2 receptor occupancy levels were estimated in clinically stable patients with schizophrenia (DSM-IV) who were receiving risperidone or olanzapine. Using two collected plasma samples, plasma antipsychotic concentrations at peak and trough were estimated with population pharmacokinetic techniques. Corresponding dopamine D2 receptor occupancy levels were then estimated, using a recently developed model. 35 subjects with stable schizophrenia completed the study (mean ± SD age, 48.8 ± 13.8. years; male [N = 14]; Asians [N = 23], Caucasians [N = 12]; risperidone [N = 20] at 3.2 ± 2.3. mg/day, and olanzapine [N = 15] at 9.2 ± 4.9. mg/day) between September and December 2010. 48.6% (N = 17) did not achieve a continuous blockade of ≥ 65%. Moreover, 11.4% (N = 4) did not achieve the 65% threshold at estimated peak concentrations. In conclusion, approximately half the subjects with stable schizophrenia did not achieve estimated continuous blockade of D2 receptor occupancy of ≥ 65%. The results suggest that sustained D2 receptor occupancy levels of ≥ 65% may not always be necessary for the maintenance treatment of schizophrenia.

KW - Antipsychotic

KW - Dopamine

KW - Maintenance

KW - Olanzapine

KW - Risperidone

KW - Schizophrenia

UR - http://www.scopus.com/inward/record.url?scp=84862787687&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862787687&partnerID=8YFLogxK

U2 - 10.1016/j.pnpbp.2011.12.013

DO - 10.1016/j.pnpbp.2011.12.013

M3 - Article

VL - 37

SP - 182

EP - 187

JO - Progress in Neuro-Psychopharmacology and Biological Psychiatry

JF - Progress in Neuro-Psychopharmacology and Biological Psychiatry

SN - 0278-5846

IS - 1

ER -